TCM
DSGN icon

Tekla Capital Management’s Design Therapeutics DSGN Stock Holding History

Tekla Capital Management’s Portfolio DSGN Stock Details DSGN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q4 		– Sell
-280,523
Closed -$4.69M – 173
2022
Q3 		$4.69M Buy
280,523
+172,109
+159% +$3.42M 0.19% 82
2022
Q2 		$1.52M Buy
108,414
+43,063
+66% +$582K 0.06% 121
2022
Q1 		$1.05M Hold
65,351
– – 0.04% 145
2021
Q4 		$1.4M Buy
+65,351
New +$1.12M 0.05% 138

Other funds holding DSGN

SOCM
SR One Capital Management Wayne, Pennsylvania $915M AUM 209.71% 1-Year Est. Return
CAM
Cormorant Asset Management Boston, Massachusetts $1.99B AUM 737.95% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
LGM
Logos Global Management San Francisco, California $2B AUM 444.09% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Tekla Capital Management's DSGN Position: Q4 2022 in Review

Tekla Capital Management sold out of Design Therapeutics (DSGN) in Q4 2022, closing a stake of 280,523 shares — an estimated $4.69M sold.

Tekla Capital Management first reported a position in DSGN in Q4 2021 and held it in 4 quarters. The position peaked at $4.69M in Q3 2022. 83 funds tracked by Wall St. Rank hold DSGN as of Q4 2022.

  • Tekla Capital Management reported no remaining Design Therapeutics position as of Q4 2022 after selling out during the quarter.
  • Tekla Capital Management sold 280,523 Design Therapeutics shares in Q4 2022, an estimated $4.69M.
  • Tekla Capital Management first reported a position in Design Therapeutics in Q4 2021 and held it in 4 quarters.
  • Tekla Capital Management's Design Therapeutics position peaked at $4.69M in Q3 2022.
  • 83 funds tracked by Wall St. Rank held Design Therapeutics as of Q4 2022.

Based on Tekla Capital Management's 13F filing for Q4 2022, filed 10 Feb 2023.